Group 1 - The core viewpoint of the article indicates a structural optimism for the pharmaceutical distribution industry in China despite the mid-term performance not turning profitable by the first half of 2025 [1] - Factors contributing to this optimism include potential relaxation of mainland medical insurance spending, possible optimization of volume-based procurement due to anti-involution measures in the healthcare sector, enhanced cash payment capabilities of medical insurance funds, and a domestic interest rate reduction cycle that may help distributors improve financial leverage [1] Group 2 - Citic Lyon raised the target price for China National Pharmaceutical Group (01099) by 22.5%, from HKD 20 to HKD 24.5 [1] - The target price for Shanghai Pharmaceuticals (02607) H-shares was increased by 15.4%, from HKD 12.3 to HKD 14.2 [1] - However, the target price for China Resources Pharmaceutical (03320) was lowered by 5.1%, from HKD 5.9 to HKD 5.6 [1] - The rating for all the mentioned companies remains "outperform the market," with China National Pharmaceutical Group being the preferred choice [1]

Core Viewpoint - The report from Citi expresses a structurally optimistic outlook for the Chinese pharmaceutical distribution industry despite the lack of a turnaround in the first half of the year [1] Group 1: Industry Insights - Potential easing of medical insurance expenditures is anticipated, which may positively impact the industry [1] - Possible optimization of centralized procurement policies is expected due to potential anti-involution measures in the healthcare sector [1] - Strengthening of direct cash settlement from medical insurance funds is noted as a positive development for the industry [1] - The domestic interest rate cut cycle is expected to improve the financial leverage of distributors [1] Group 2: Company Target Price Adjustments - The target price for China National Pharmaceutical Group (国药控股) is raised from HKD 20 to HKD 24.5 [1] - The target price for Shanghai Pharmaceuticals (上海医药) is increased from HKD 12.3 to HKD 14.2 [1] - The target price for China Resources Pharmaceutical (华润医药) is decreased from HKD 5.9 to HKD 5.6, while maintaining an "outperform" rating [1] - China National Pharmaceutical Group is identified as the preferred choice among pure distributors [1]

Core Viewpoint - The report from Credit Lyonnais indicates a structurally optimistic outlook for the Chinese pharmaceutical distribution industry despite the lack of a turnaround in the first half of the year [1] Industry Summary - Potential easing of medical insurance expenditures is anticipated, which could positively impact the industry [1] - Possible anti-involution measures in the healthcare sector are expected to optimize centralized procurement policies [1] - Strengthening of direct cash settlement from medical insurance funds is noted as a beneficial factor [1] - The domestic interest rate cut cycle is expected to improve the financial leverage of distributors [1] Company Summary - Credit Lyonnais raised the target price for China National Pharmaceutical Group (Sinopharm) from HKD 20 to HKD 24.5 [1] - The target price for Shanghai Pharmaceuticals' H-shares was increased from HKD 12.3 to HKD 14.2 [1] - The target price for China Resources Pharmaceutical was slightly decreased from HKD 5.9 to HKD 5.6, while maintaining an "outperform" rating [1] - Sinopharm is identified as the preferred choice among pure distributors by Credit Lyonnais [1]

Drug Overview - Shanghai Pharmaceuticals has received a drug registration certificate from the Philippines Food and Drug Administration for Aripiprazole Tablets, allowing the product to be marketed in the Philippines [1] - Aripiprazole is an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and can also be used as an adjunct treatment for depression [1] - The drug was first approved by the FDA in the United States in November 2002 and was approved for domestic sale in China in October 2004 [1] Market Competition - In the Philippines, Aripiprazole Tablets face competition from five other companies, including OTSUKA PHARM, ZYDUS PHILS. INC., and MULTICARE PHARM [2] - The total sales revenue for Aripiprazole Tablets (10 mg) in the Philippines is projected to be $2.39 million in 2024 according to IQVIA data [3] Impact on Company - The approval of Aripiprazole Tablets in the Philippines is expected to positively impact the company's efforts to expand into overseas markets and accumulate valuable experience [4]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the Philippines Food and Drug Administration for the marketing of Aripiprazole tablets, an antipsychotic medication used for treating schizophrenia and manic episodes of bipolar disorder, and as an adjunct treatment for depression [1] Group 1 - The product approved is Aripiprazole tablets, which are primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder [1] - Aripiprazole can also be used as an adjunct treatment for depression [1] - The approval signifies a potential expansion of the company's product offerings in the pharmaceutical market [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Philippines Food and Drug Administration for the marketing of Aripiprazole tablets produced by its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. This approval marks a significant milestone for the company in expanding its product offerings in the international market [1]. Group 1: Product Information - Aripiprazole tablets are an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and can also serve as an adjunct treatment for depression [1]. - The drug was developed by Bristol-Myers Squibb and Otsuka Pharmaceutical, first receiving FDA approval in the United States in November 2002 under the brand name Abilify® [1]. - Shanghai Shiyou Zhongxi's Aripiprazole tablets were approved for domestic sale in China in October 2004, and the 5mg specification of both Aripiprazole tablets and capsules passed the consistency evaluation for generic drugs in March 2021 [1]. Group 2: Financial and Regulatory Aspects - The company has invested approximately RMB 50,000 in registration-related expenses for the drug's approval in the Philippines [1].

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 9 月 13 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於阿立呱唑片獲得菲律賓藥品註冊證書的公告》僅供 參閱。 上海医药集团股份有限公司 关于阿立 ...

上海医药集团股份有限公司 关于阿立哌唑片获得菲律宾药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海上药中西制药有限公司（以下简称"上药中西"）生产的阿立哌唑片（以 下简称"该药品"）收到菲律宾食品药品监督管理局颁发的药品注册证书，该药 品获得批准上市。 一、药品基本情况 药品名称：阿立哌唑片 注册证号：DRP-16802 二、药品相关的信息 证券代码：601607 证券简称：上海医药 编号：临2025-082 三、药品市场竞争情况 截至本公告日，在菲律宾境内阿立哌唑片主要有 OTSUKA PHARM，ZYDUS PHILS. INC.，MULTICARE PHARM 等其他 5 家销售商。 IQVIA 数据库显示，2024 年菲律宾市场阿立哌唑片（10 mg）合计销售额为 239 万美元。 四、对上市公司影响及风险提示 本次阿立哌唑片（10 mg）获得菲律宾食品药品监督管理局的药品注册批文， 标志着公司具备了在菲律宾市场销售该药 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. (referred to as "Shiyou Zhongxi"), has received a drug registration certificate from the Philippines Food and Drug Administration for Aripiprazole Tablets, which have been approved for market launch [1] Group 1 - The drug Aripiprazole is an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and it can also be used as an adjunct treatment for depression [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Chinese-Western Medicine Co., Ltd., has received a drug registration certificate from the Philippines Food and Drug Administration for Aripiprazole tablets, which have been approved for market launch [1] Group 1 - The drug Aripiprazole is an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and it can also be used as an adjunct treatment for depression [1]